Skip to main content
RNA logoLink to RNA
. 2015 Oct;21(10):1826–1833. doi: 10.1261/rna.052225.115

eIF4AII is dispensable for miRNA-mediated gene silencing

Gabriela Galicia-Vázquez 1,4, Jennifer Chu 1,4, Jerry Pelletier 1,2,3
PMCID: PMC4574758  PMID: 26286746

Abstract

MicroRNAs (miRNAs) are short noncoding RNAs that regulate gene expression through partial complementary base-pairing to the 3′ untranslated region (UTR) of target mRNAs. Inhibition of translation initiation has been identified as an early event of miRNA-mediated gene repression, but the underlying mechanistic details of this process are not well understood. Recently, eukaryotic initiation factor (eIF) 4AII was identified as a critical modulator of miRNA activity with depletion of this factor alleviating miRNA-mediated gene repression. Using the CRISPR/Cas9-editing system, we generated a novel cell line in which expression of eIF4AII was eliminated. The absence of eIF4AII does not affect cell viability, proliferation, or global mRNA translation. Importantly, we show that eIF4AII is dispensable for miRNA-mediated gene silencing.

Keywords: eIF4AII, RISC, miRNA, CRISPR, Cas9, genome editing

INTRODUCTION

MicroRNAs (miRNAs) are short (∼21 nt) noncoding RNAs that post-transcriptionally regulate gene expression by assembling into miRNA-induced silencing complexes (miRISC) (Fabian et al. 2010). Typically, miRNAs exert their repressive influence through association with Argonaute (Ago) and GW182 proteins to form the miRISC and imperfectly hybridizing to target mRNAs. Subsequent inhibition of translation and/or mRNA deadenylation and decay is thought to lead to mRNA-specific silencing. Although the relative (and temporal) contribution of translation inhibition versus mRNA degradation to miRNA-mediated gene silencing remains controversial (Eichhorn et al. 2014), kinetic studies have demonstrated that translation inhibition precedes degradation and is the predominant repressive mechanism operative at early time points following miRISC formation (Fabian et al. 2009; Béthune et al. 2012; Djuranovic et al. 2012; Eichhorn et al. 2014).

Among the mechanisms implicated in translational repression by miRNAs, inhibition of cap-dependent initiation has been invoked from in vitro and in vivo studies (Pillai et al. 2005; Wang et al. 2006; Mathonnet et al. 2007). Of note is the finding that type II internal ribosome entry sites (IRESes), which direct translation initiation in the absence of the cap-binding protein, eukaryotic initiation factor (eIF) 4E, are refractory to miRNA-mediated repression (Humphreys et al. 2005; Mathonnet et al. 2007) thus implicating a role for eIF4E or the 5′ m7G cap structure in this process. Consistent with this is the requirement of a cap structure for efficient miRNA-mediated silencing and the finding that the eIF4F complex (consisting of eIF4E, the DEAD-box eIF4A helicase, and the eIF4G scaffolding protein) can alleviate miRNA activity repression in vitro (Pillai et al. 2005; Wang et al. 2006; Mathonnet et al. 2007). Taken together, these results suggest that miRNAs may target the translation initiation apparatus by promoting disassembly of, or impairing cap recognition by, the eIF4F complex (Mathonnet et al. 2007). Recent experiments have also implicated a critical role for the eIF4A subunit of the eIF4F complex in this process (Meijer et al. 2013; Fukao et al. 2014).

In mammals, two eIF4A paralogs (eIF4AI and eIF4AII) sharing >90% identity, assemble into the eIF4F complex (Yoder-Hill et al. 1993; Rogers et al. 2002). The translation of most cellular mRNAs is dependent on eIF4A, although the degree to which they require eIF4A is related, in part, to the presence of a secondary structure within the mRNA 5′ untranslated region (UTR) (Bhat et al. 2015; Pelletier et al. 2015). The levels of eIF4AI and eIF4AII have been assessed in various tissues and cell lines, and generally eIF4AI is the more abundant paralog (Nielsen et al. 1985; Nielsen and Trachsel 1988; Galicia-Vázquez et al. 2012). Although both proteins are thought to participate in translation initiation, there is evidence suggesting that eIF4AI and eIF4AII are not redundant proteins and may possess unique biological properties (Li et al. 2001; Galicia-Vázquez et al. 2012). The dissociation of eIF4AI and eIF4AII from target mRNAs is thought to be an early step of miRISC-mediated translational repression (Fukao et al. 2014; Fukaya et al. 2014). Consistent with this, the stabilization of eIF4A onto mRNAs using the pharmacological inhibitor, silvestrol, has been shown to dampen miRNA repression (Fukao et al. 2014). However, another study invoked a critical role for eIF4AII, but not eIF4AI, in miRNA-mediated repression (Meijer et al. 2013). Here, it was proposed that eIF4AII is the only eIF4F component required for miRNA-mediated repression and that it interacts with CNOT1 to induce deadenylation (Meijer et al. 2013). To test the relevance of eIF4AII in miRNA silencing, we used CRISPR/Cas9-mediated genome editing to generate an eIF4AII null cell line. We show that the absence of eIF4AII does not affect cell viability or global protein synthesis, and is not required for efficient siRNA- or miRNA-mediated gene regulation.

RESULTS

We utilized CRISPR/Cas9-editing technology to eliminate eIF4AII in NIH/3T3 cells to dissect potential biological differences between eIF4AI and eIF4AII. Our approach was to design a sgRNA that targeted exon 5, which contains the conserved RNA-binding TPGR motif Ib to disrupt expression of full-length wild-type protein (Fig. 1A). Following introduction of the CRISPR/Cas9-editing system into NIH/3T3 cells, 168 GFP+ single-cell clones were isolated by limiting dilution and screened by PCR using “Primers 4AII” (Table 1; Fig. 1A). Genomic DNA from one of the isolated clones failed to yield a PCR product with this primer pair, despite being of sufficient quality to produce a PCR product from the eIF4AI locus (Fig. 1B, cf. lane 3 to lanes 1 and 2). This clone, designated eIF4AIIem1JP (for the first endonuclease-induced mutation [em1] of the eIF4AII gene produced in the JP laboratory) (http://www.informatics.jax.org/mgihome/nomen/gene.shtml#endim) was chosen for further characterization. Using a more recessed, second primer pair (4AIIext), two shorter than expected PCR products were obtained (Fig. 1B). Sequencing of the larger PCR product revealed a 673 bp product with a 109 bp deletion within exon 5, which we refer to as Δ1 (Fig. 1C). In this case, repair of the double-stranded break generated by Cas9 may have been mediated by microhomology-mediated NHEJ (see highlighted sequences in Fig. 1A,C). Sequencing of the shorter 4AIIext product corresponded to a 588 bp fragment that arose as a result of mispriming of Primer 4AIIext-Rev (Table 1) within eIF4AII intron 8. This fortuitous event uncovered a second larger deletion, Δ2, extending from exon 5 to exon 8 with an extra adenine inserted at the junction point (Fig. 1D). Deletions Δ1 and Δ2 were also detected using a different primer pair spanning from intron 4 to intron 8 (4AIIext-b) (Fig. 1B), which upon sequencing, yielded products harboring the expected mutations.

FIGURE 1.

FIGURE 1.

(A) Generation of NIH/3T3 eIF4AIIem1JP cells. Schematic diagram illustrating the exon/intron structure of the murine eIF4AII gene and denoting exon 5 (orange shading; downward arrow) targeted by Cas9 for deletion mutagenesis. The positions of the primers used to characterize the eIF4AII locus following CRISPR/Cas9-mediated gene editing are shown. The red sequence denotes the region to which the Cas9 sgRNA was designed and the underlined 5′-GGG-3′ triplet indicates the position of the PAM motif. The orange highlighted sequence denotes a duplicated region that likely led to microhomology-mediated NHEJ to generate Δ1 (see text for details). The TPGR motif 1b is shown in green. (B) PCR analysis of eIF4AIIem1JP. DNA was isolated from parental NIH/3T3 cells (lane 1), NIH/3T3 cells expressing Cas9 and an sgRNA targeting the neutral Rosa26 locus (Malina et al. 2013) (lane 2), or eIF4AIIem1JPcells (lane 3) and used in PCRs with the indicated primer pairs (Table 1). PCR products were analyzed on 1% agarose gels. Products were excised from the gel and analyzed by direct sequencing. (C) Schematic diagram representing configuration of the Δ1 eIF4AII allele in eIF4AIIem1JP. (D) Schematic diagram representing configuration of the Δ2 eIF4AII allele in eIF4AIIem1JP. (E) RT-PCR analysis of mRNA isolated from the indicated cell lines. Complementary DNA was generated as indicated in Materials and Methods using an eIF4AII-specific primer. PCRs were performed using the indicated primer pairs and products analyzed on a 1.2% agarose gel. Products were excised from the gel and analyzed by direct sequencing. (F) RT-qPCR analysis of eIF4AII mRNA in NIH/3T3 and eIF4AIIem1JP cells. Expression of eIF4AII was calculated relative to GAPDH levels and is based on ΔΔCT values. (G) Western blot probing of extracts prepared from NIH/3T3 (lane 1) or eIF4AIIem1JP (lane 2) using antibodies directed to the proteins shown to the right. (H) Western blot probing of extracts prepared from NIH/3T3 (lane 1) or eIF4AIIem1JP (lane 2) using an N-terminal directed antibody (ab31218, Abcam). Arrow indicates position of migration of eIF4AII.

TABLE 1.

PCR Primers used in the current study

graphic file with name 1826TB01.jpg

We then analyzed the structure of the expected eIF4AII mRNA using primers spanning from exons 4 to 9 and obtained cDNA products and confirmed the presence of Δ1 and Δ2 mRNA transcripts in eIF4AIIem1JP cells via sequencing (Fig. 1E). An additional product (554 bp) was obtained following RT-PCR, which upon sequencing, corresponded to an mRNA lacking exon 5 (ΔExon 5: exon 4 was fused to exon 6) (see Discussion). We saw no evidence for a full-length eIF4AII transcript spanning exons 4–9 in eIF4AIIem1JP cells and all mutations are predicted to cause frameshifts resulting in early termination of translation (Δ1, 14.2 kDa; ΔExon 5, 14.6 kDa; Δ2, 20.2 kDa).

Quantitative RT-PCR analysis of the eIF4AII mRNA in eIF4AIIem1JP cells, with primers targeting exon 1 or spanning exons 2–4, revealed an approximately fourfold decrease in mRNA levels (Fig. 1F). Although we have not investigated the mechanism responsible for this decrease, it may be attributable to nonsense-mediated decay, effects on transcriptional output, and/or mRNA stability. Importantly, Western blot analysis of total protein extracts from NIH/3T3 and eIF4AIIem1JP cells revealed the absence of eIF4AII in the latter, with no significant changes in eIF4AI, eIF4E, and eIF4GI levels (Fig. 1G; P-values: 0.90 for eIF4AI, 0.74 for eIF4E, and 0.93 for eIF4GI). Using an antibody targeting the eIF4AII N-terminal domain, we failed to note the presence of truncated products arising from Δ1, ΔExon 5, or Δ2 mRNA transcripts (∼14–20 kDa), indicating that, if produced, these are below the limits of detection of our probings (Fig. 1H).

We previously documented that knockdown of eIF4AI, but not eIF4AII, dramatically inhibits protein synthesis and is lethal in Myc-driven tumors (Galicia-Vázquez et al. 2012; Cencic et al. 2013). We took advantage of the complete absence of eIF4AII in eIF4AIIem1JP to assess the consequences on global protein synthesis and cellular proliferation. We found that relative to the parental NIH/3T3 cell line or to a cell line in which Cas9 had been targeted to the neutral Rosa26 locus (referred to hereafter as NIH/3T3[sgROSA]), eIF4AIIem1JP showed no detectable differences in 35S-methionine incorporation or cellular proliferation (Fig. 2). We conclude that eIF4AII is not essential and that its loss in NIH/3T3 cells has no noticeable impact on global protein synthesis.

FIGURE 2.

FIGURE 2.

(A) Loss of eIF4AII does not affect global translation or cellular viability. Quantitation of protein synthesis in NIH/3T3 and eIF4AIIem1JP cells. Protein synthesis was determined as described in Materials and Methods. N = 3 biological replicates (performed in technical duplicates) ± SEM. (B) Population doubling level (PDL) of NIH/3T3 and eIF4AIIem1JP cells. N = 3 biological replicates (performed in technical duplicates) ± SEM.

These results were surprising since eIF4AII has been reported to be essential for microRNA-mediated gene regulation (Meijer et al. 2013) and loss of miRNA function is associated with perturbed proliferative and survival responses (e.g., as documented in Dicer−/− cells) (Ravi et al. 2012). We thus took advantage of eIF4AIIem1JP cells to characterize siRNA and miRNA activity in the absence of eIF4AII. To this end, we assessed gene expression from two reporter systems in NIH/3T3[sgROSA] or eIF4AIIem1JP cells transduced with shRNAs targeting GFP or Ago2 (Fig. 3A). First, we probed for effects of eIF4AII loss on siRNA-mediated gene repression. We introduced a Renilla luciferase (RLuc)-based reporter carrying six artificial CXCR4 siRNA-binding sites, along with a control scrambled (siScr) or CXCR4 siRNA, into each of the cell lines, and assessed subsequent repression by measuring luciferase activity (Fig. 3B; Wang et al. 2009). A plasmid coding for HCV-Firefly Luciferase (FLuc) was used as a transfection control. The RLuc expression data were normalized to FLuc activity and indicated significant loss of siRNA-mediated repression upon Ago2 suppression in both NIH/3T3[sgROSA] and eIF4AIIem1JP cells (Fig. 3B). There was no significant difference in response between NIH/3T3[sgROSA] and eIF4AIIem1JP cells transduced with shGFP. Second, we utilized a set of reporters whose translation is regulated by endogenous let-7 (Fig. 3C; Mathonnet et al. 2007). In both shGFP infected cell lines, expression from the pRL 6xLet7 reporter was significantly reduced compared to pRL mm6xLet7, indicating regulation by endogenous mouse Let-7 (Fig. 3D). Of note, derepression of the pRL 6xLet7 reporter was observed upon knockdown of Ago2 in both cell lines, whereas expression from reporters lacking Let-7 binding sites (pRL) or harboring mutated seed regions (pRL mm6xLet7) were unchanged (Fig. 3D). No significant difference in response was noticed between the shGFP infected NIH/3T3[sgROSA] and eIF4AIIem1JP cells (Fig. 3D). Taken together, these results indicate that eIF4AII is not necessary for siRNA- or miRNA-mediated regulation of gene expression.

FIGURE 3.

FIGURE 3.

(A) Western blot assessing suppression of Argonuate-2 (Ago2) in NIH/3T3 and eIF4AIIem1JP cells. Cells were transduced with lentivirus expressing an shRNA targeting Ago2 (TRCN0000255786) or shGFP (SHC002) and extracts were probed with the indicated antibodies by Western blotting. (B) Suppression of gene expression by siRNAs is unaffected by loss of eIF4AII. (Top panel) Schematic representation of the Renilla Luciferase (RLuc) reporter harboring six siCXCR4 binding sites. (Bottom panel) Bar graph reporting on expression levels obtained from the indicated cells transfected with RL6X and pcDNA3-HCV-FLuc in the presence of a scrambled siRNA control (siScr: Dharmacon's ON-TARGETplus Non-targeting siRNA #1) or CXCR4 siRNA (5′-UGUUAGCUGGAGUGAAAAC-3′) (Wang et al. 2009). Luciferase activities were measured 48 h post-transfection. The fold siCXCR4 repression was determined by normalizing RLuc/FLuc values to the values obtained in the presence of the scramble siRNA control. N = 3 biological replications, with each experiment performed with technical triplicates ± SEM. (*) P < 0.05; n.s., P > 0.9. (C) Schematic representation of reporters used to assess miRNA activity. (D) Let7 miRNA-mediated repression is unaffected by loss of eIF4AII. Bar graph reporting on expression levels obtained from the indicated cells transfected with pRL reporters and HCV/FLuc. Luciferase activities were quantitated 48 h post-transfection and plotted with respect to values obtained with the pRL control vector. N = 3 biological replicates (performed in technical triplicates) ± SEM. (**) P < 0.01; n.s., P > 0.15.

Although none of the alleles disrupted in eIF4AIIem1JP cells can produce functional eIF4AII protein, it is a formal possibility that a truncated form could be generated (albeit at significantly reduced levels [Fig. 1F]) that could participate in RNA-mediated silencing—perhaps as a scaffold for complex assembly. We therefore suppressed eIF4AII mRNA levels in NIH/3T3[sgROSA] and eIF4AIIem1JP cells using two previously characterized independent shRNAs (Fig. 4A; Galicia-Vázquez et al. 2012) and monitored the consequences on siRNA- and miRNA-mediated silencing (Fig. 4B,C). We saw no evidence for changes to suppression of our reporter constructs when eIF4AII mRNA levels were further suppressed in eIF4AIIem1JP cells, indicating that any truncated products, if synthesized, are unlikely to be participating in RNA-mediated regulation of gene expression. These results were not cell type specific as potent knockdown of eIF4AII in HeLa cells showed no effects on siRNA- or miRNA-mediated gene expression when compared to control cells (Fig. 4D,E).

FIGURE 4.

FIGURE 4.

(A) RT-qPCR analysis of eIF4AII mRNA levels in NIH/3T3[sgROSA] and eIF4AIIem1JP cells following infections with retroviruses expressing shRNAs targeting eIF4AII. (B) siRNA-mediated suppression is unaffected by eIF4AII knockdown in NIH/3T3[sgROSA] or eIF4AIIem1JP cells. Cells were transduced with shRNAs targeting eIF4AII 24 h prior to assessing siRNA-mediated suppression, as described in Figure 3B. (C) Let-7–mediated miRNA repression is unaffected by eIF4AII knockdown. NIH/3T3[sgROSA] or eIF4AIIem1JP cells were transduced with shRNAs targeting eIF4AII 24 h prior to assessing miRNA-mediated suppression, as described in Figure 3D. (D) Representative Western blot of HeLa cells transfected with either nontargeting (siNT) or eIF4AII (si4AII) siRNAs. (E) miRNA-mediated gene repression is not affected by loss of eIF4AII in HeLa cells. HeLa cells were transfected with either eIF4AII siRNAs or a nontargeting siRNA control 24 h prior to assessing siRNA—and miRNA-mediated repression as described above. N = 2 biological replications, with each experiment performed with technical triplicates ± SEM.

Finally, to assess whether the loss of eIF4AII altered miRNA-mediated repression of endogenous transcripts, we transfected NIH/3T3[sgROSA] and eIF4AIIem1JP cells with an antagomir to let-7c (referred to hereafter as Anti-let-7c) and measured the consequences on the expression of HMGA2, a well-characterized target of let-7 miRNAs (Lee and Dutta 2007; Mayr et al. 2007). RT-qPCR shows that introduction of Anti-let-7c led to a sixfold to sevenfold increase in HMGA2 mRNA levels relative to the mock-transfected cells, irrespective to the presence of eIF4AII (Fig. 5A). Accordingly, we also observed a 1.5- to 1.6-fold increase in HMGA2 protein expression in NIH/3T3[sgROSA] and eIF4AIIem1JP cells transfected with Anti-let-7c. Taken together, our data demonstrate that miRNA-mediated repression is not impaired in eIF4AIIem1JP cells, suggesting that eIF4AII is not an essential factor for miRNA silencing.

FIGURE 5.

FIGURE 5.

(A) RT-qPCR analysis of HMGA2 mRNA expression levels. Cells were transfected with Anti-let-7c twice and total RNA was harvested 24 h after the last transfection. HMGA2 mRNA expression levels are standardized to GAPDH and plotted relative to the mock transfections for each cell line. N = 3 ± SEM. (*) P < 0.05, (**) P < 0.01. (B) Western blot assessing the effect of Anti-let-7c on HMGA2 protein levels. Cells were treated and harvested as in Figure 3A. Blots were probed with the indicated antibodies, then scanned and quantitated on the LI-COR Odyssey Image system. N = 3 ± SEM.

DISCUSSION

Here, we used CRISPR/Cas9 to generate a novel NIH/3T3 cell line in which expression of eIF4AII is ablated (Fig. 1). Genomic PCR analysis of this line indicated the presence of at least two mutated eIF4AII alleles harboring intragenic deletions, whereas RT-PCR analysis indicated the presence of three truncated mRNA transcripts. Deletion Δ1 is a 109 bp deletion that is within the size range usually obtained using the CRISPR/Cas9-editing system (Mali et al. 2013; Malina et al. 2013). The serendipitous mispriming event with primers 4AIIext, however, uncovered a larger intragenic deletion, Δ2 (Fig. 1). We do not have insight into the mechanism that led to the generation of Δ2, but it could have been the result of unpredicted off-target cutting by Cas9 near the 3′ border of the deletion. However, we failed to detect any sequence target site of sufficient homology with the eIF4AII sgRNA used in our approach (data not shown). RT-PCR analysis revealed the presence of a third transcript lacking exon 5 (Fig. 1E, ΔExon5). Whether this is the result of inefficient recognition of the splice acceptor site in exon 5 of Δ1 leading to exon skipping or the presence of a third mutated eIF4AII allele in eIF4AIIem1JP cells is currently unknown (since there is no a priori reason to assume that NIH/3T3 are diploid for eIF4AII). These results highlight that CRISPR/Cas9-editing can lead to unpredicted and complex gene rearrangements. Nonetheless, Western blot analysis indicated complete loss of all wild-type eIF4AII alleles (Fig. 1G,H).

We did not detect any significant consequence of eIF4AII loss on global protein synthesis or cellular proliferation (Fig. 2). These results reinforce our previous findings in which we used siRNAs and shRNAs to suppress eIF4AII and saw little effect on cell proliferation and viability (Galicia-Vázquez et al. 2012; Cencic et al. 2013). However, the differential regulation of eIF4AII and eIF4AI during differentiation (Galicia-Vázquez et al. 2014), growth status (Williams-Hill et al. 1997), and in response to MYC (Lin et al. 2008) are suggestive of specialized functions for eIF4AII which have not been uncovered by our assays. MicroRNAs mediate translational repression and deadenylation/mRNA decay with the sum of these processes measured by the assays utilized in our study. eIF4AII has been reported to be critical to miRNA-mediated gene regulation and Meijer et al. (2013) reported derepression of RNA silencing upon knockdown of eIF4AII. In our hands, we were unable to observe this phenomenon in HeLa cells (Fig. 4D,E). The underlying basis for this discrepancy is unclear, although our results in HeLa cells are consistent with the bulk of the data presented herein using NIH/3T3 cells lacking eIF4AII, and indicate that eIF4AII is dispensable for RNA-mediated silencing. Our data do not allow us to rule out a specialized role for eIF4AII, but it does not appear to be essential to the process. The current study also exemplified how the ability to rapidly generate isogenic cell lines using CRISPR/Cas9 is a powerful addition to the somatic cell genetics toolkit to help elucidate gene function.

CONCLUSIONS

Our results demonstrate that eIF4AII activity is neither essential nor required for miRNA-mediated gene silencing or reporter mRNAs in mammalian cells.

MATERIALS AND METHODS

Generation of eIF4AIIem1JP cells

NIH/3T3 cell lines were cultured in DMEM supplemented with 10% FBS, 100 U/mL penicillin/streptomycin, and 4 mM l-glutamine at 37°C and 5% CO2. A previously described pQCX-based All-In-One vector system (Malina et al. 2013) expressing an sgRNA targeting eIF4AII exon 5 (5′-GCATTGTTGTTGGTACTCCA-3′) (Fig. 1A), human codon-optimized Cas9, and GFP was introduced into NIH/3T3 cells by nucleofection of 2.5 µg of plasmid (Amaxa Cell Line Nucleofector KitR for NIH/3T3, VCA-1001, Lonza) using program U-030 and an Amaxa Nucleofector device. After 48 h, GFP+ cells were isolated by cell sorting with a FACSAria-Cell Sorter (BD Biosciences). One hundred and sixty-eight single-cell clones were isolated by limiting dilution. Upon expansion, DNA was isolated and screening performed by PCR using Phusion High-Fidelity DNA polymerase (New England BioLabs) (Table 1).

Retroviral transductions

Twenty-five micrograms of MLS-empty, MLS-sh4AII.485 or MLS-sh4AII.592 was transfected into ectropic Phoenix cells using calcium phosphate in the presence of 25 μM chloroquine. The media was changed the following day and 48 h post-transfection, the viral supernatant was collected, filtered, and added to NIH/3T3[sgROSA] or eIF4AIIem1JP cells in the presence of 4 μg/mL polybrene. Cells were infected six times every 8 h by spinoculation at 1000g for 1 h at 30°C.

Cell doubling assays

NIH/3T3 (10,000 cells) were seeded in 12-well plates at the beginning of each passage. After 2 d, cells were trypsinized, counted by flow cytometry (GUAVA EasyCyte Plus; Millipore) and the data analyzed using Cytosoft 5.3 Software. Cells were then reseeded for the next passage analysis. Population doubling level for each passage was calculated with the following equation: Cumulative PDL = [Log(Final cell number/Initial cell number)/Log(2)] + Starting PDL (Hayflick 1973; Faraonio et al. 2012).

Monitoring siRNA and miRNA activity

To assess siRNA activity, a previously reported Renilla luciferase expression vector (RL6X) harboring six CXCR4 siRNA-binding sites was utilized (Wang et al. 2006). Twelve hours prior to transfection, 50,000 cells were seeded per well in a 12-well plate. In each well, 1 μg RL6X, 1 μg pcDNA3-HCV-FLuc, and 12 pmol of siRNA were co-transfected using Lipofectamine 2000 according to the manufacturer's instructions (Life Technologies). In experiments involving transient suppression of eIF4AII using siRNAs, HeLa cells were transfected with siRNAs targeting human eIF4AII (M-013758-01) using Lipofectamine 2000 24 h prior to transfection of the luciferase reporters.

To assess miRNA activity, we utilized previously described Renilla luciferase reporters harboring either no (pRL) or 6 (pRL 6xLet7) let-7 target sites in addition to a Renilla luciferase reporter with 6 let-7 target sites containing mutations within its seed sequence (pRL mm6xLet7). The reporter plasmids were co-transfected with pcDNA-HCV-FLuc using Lipofectamine 2000 according to the manufacturer's instructions. Twenty-four hours post-transfection, cells were reseeded into a 96-well plate. Forty-eight hours post-transfection, cells were lysed with 1× Passive lysis buffer (Promega) and luciferase activities were measured using the Dual-Glo Luciferase System (Promega).

Immunoblotting analysis

Protein samples were fractionated on SDS-polyacrylamide gels, transferred to PVDF membrane (Millipore), and probed with the indicated antibodies. Antibodies used in this study were directed against: eIF4AI (ab31217, Abcam), eIF4AII (ab31218, Abcam), eIF4E (Cell Signaling), eIF4GI (A300-502A, Bethyl Labs), PDCD4 (cs9535, Cell Signaling), Tubulin (T5168, Sigma), Actin (A5441, Sigma), GAPDH (ab8245, Abcam), Ago2 (C34C6, Cell Signaling), and HMGA2 (ab97276, Abcam). For statistical analysis, Student t-tests were performed using GraphPad InStat version 3.10.

[35S]-Methionine/cysteine metabolic labeling

Cells were preincubated in methionine/cysteine-free DMEM with 10% dialyzed FBS and 4 mM l-glutamine for 40 min prior to the addition of [35S]-methionine/cysteine (150–200 μCi/mL; 1175 Ci/mmol) (PerkinElmer). Cells were labeled for 20 min and levels of [35S]-methionine/cysteine incorporation were determined from cell extracts by TCA precipitation followed by scintillation counting. CPMs obtained were normalized to protein levels in the extracts and are plotted relative to the values obtained with the parental NIH/3T3 cells.

RT-PCR

Cellular RNA was isolated using TRIzol (Invitrogen). Complementary DNA was generated by reverse transcription using SuperScript III (Invitrogen) and 4AII-Exon9 Rev primer (5′-AGTGATCAGAACACGGCTTGA-3′) according to the manufacturer's instructions. Amplifications were performed by Touchdown PCR using Phusion High-Fidelity DNA Polymerase (New England BioLabs) and 4AIIexon-4/9 primers, with annealing temperatures ranging from 67°C to 57°C (Table 1). To quantify eIF4AII mRNA levels, reverse transcription was performed using Superscript III (Invitrogen) and Oligo dT (Invitrogen). Quantitative PCRs were performed using SsoFast Evagreen Supermix (Bio-Rad). Reactions were performed using a CFX96 PCR System (Bio-Rad), and data analyzed using Bio-Rad CFX Manager 2.1 software. The threshold cycles (CTs) were determined by single threshold, and the expression of eIF4AII was determined by the ΔΔCT method using GAPDH as the reference target. Primer efficiency was determined and taken into account in the CT expression determinations.

Probing endogenous miRNA repression

Approximately, 200,000 cells were seeded per well in a 6-well plate and transfected with 250 pmol of Anti-miR hsa-let-7c miRNA Inhibitor (Ambion) using Lipofectamine 2000 according to the manufacturer's instructions. Media was changed 24 h later and a second transfection performed 48 h later. RNA and protein were extracted 24 h after the final transfection. For mRNA expression analysis, total RNA was extracted using TRIzol and cDNA was produced using SuperScript III Reverse Transcriptase (Invitrogen). Quantitative PCRs were performed with SsoFast EvaGreen Supermix (Bio-Rad) using primers specific to HMGA2 and GAPDH. Relative expression of HMGA2 mRNA was determined using the 2−ΔΔCT method (Livak and Schmittgen 2001), with GAPDH as the reference transcript. To assess HMGA2 protein levels, cells were lysed in RIPA buffer (20 mM HEPES7.5, 150 mM NaCl, 1% Triton-X100, 10% glycerol, 1 mM EDTA, 10 mM tetrasodium pyrophosphate, 100 mM NaF, 17.5 mM β-glycerophosphate, 1mM PMSF, 4 μg/mL aprotinin, 2 μg/mL leupeptin, 2 μg/mL pepstatin) and processed for immunoblotting. Blots were scanned and quantitated using the LI-COR Odyssey Image system (v3.0).

ACKNOWLEDGMENTS

We are grateful to Drs. Nahum Sonenberg (McGill University) and Marc Fabian (Lady Davis Institute for Medical Research, McGill University) for their helpful comments on the manuscript. The RL6X expression vector was a kind gift from Dr. Carl Novina (Dana-Farber/Harvard Cancer Center, MA). Plasmids pRL, pRL 6xLet7, and pRL mm6xLet7 were kind gifts from Dr. Witold Filipowicz (Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland). J.C. was supported by a MICRTP (McGill Integrated Cancer Research Training Program) studentship. Funding was provided by a grant from the Canadian Institutes of Health Research (MOP#115126).

Footnotes

Article published online ahead of print. Article and publication date are at http://www.rnajournal.org/cgi/doi/10.1261/rna.052225.115.

REFERENCES

  1. Béthune J, Artus-Revel CG, Filipowicz W. 2012. Kinetic analysis reveals successive steps leading to miRNA-mediated silencing in mammalian cells. EMBO Rep 13: 716–723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bhat M, Robichaud N, Hulea L, Sonenberg N, Pelletier J, Topisirovic I. 2015. Targeting the translation machinery in cancer. Nat Rev Drug Discov 14: 261–278. [DOI] [PubMed] [Google Scholar]
  3. Cencic R, Robert F, Galicia-Vázquez G, Malina A, Ravindar K, Somaiah R, Pierre P, Tanaka J, Deslongchamps P, Pelletier J. 2013. Modifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A. Blood Cancer J 3: e128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Djuranovic S, Nahvi A, Green R. 2012. miRNA-mediated gene silencing by translational repression followed by mRNA deadenylation and decay. Science 336: 237–240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Eichhorn SW, Guo H, McGeary SE, Rodriguez-Mias RA, Shin C, Baek D, Hsu SH, Ghoshal K, Villén J, Bartel DP. 2014. mRNA destabilization is the dominant effect of mammalian microRNAs by the time substantial repression ensues. Mol Cell 56: 104–115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fabian MR, Mathonnet G, Sundermeier T, Mathys H, Zipprich JT, Svitkin YV, Rivas F, Jinek M, Wohlschlegel J, Doudna JA, et al. 2009. Mammalian miRNA RISC recruits CAF1 and PABP to affect PABP-dependent deadenylation. Mol Cell 35: 868–880. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fabian MR, Sonenberg N, Filipowicz W. 2010. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 79: 351–379. [DOI] [PubMed] [Google Scholar]
  8. Faraonio R, Salerno P, Passaro F, Sedia C, Iaccio A, Bellelli R, Nappi TC, Comegna M, Romano S, Salvatore G, et al. 2012. A set of miRNAs participates in the cellular senescence program in human diploid fibroblasts. Cell Death Differ 19: 713–721. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Fukao A, Mishima Y, Takizawa N, Oka S, Imataka H, Pelletier J, Sonenberg N, Thoma C, Fujiwara T. 2014. MicroRNAs trigger dissociation of eIF4AI and eIF4AII from target mRNAs in humans. Mol Cell 56: 79–89. [DOI] [PubMed] [Google Scholar]
  10. Fukaya T, Iwakawa HO, Tomari Y. 2014. MicroRNAs block assembly of eIF4F translation initiation complex in Drosophila. Mol Cell 56: 67–78. [DOI] [PubMed] [Google Scholar]
  11. Galicia-Vázquez G, Cencic R, Robert F, Agenor AQ, Pelletier J. 2012. A cellular response linking eIF4AI activity to eIF4AII transcription. RNA 18: 1373–1384. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Galicia-Vázquez G, Di Marco S, Lian XJ, Ma JF, Gallouzi IE, Pelletier J. 2014. Regulation of eukaryotic initiation factor 4AII by MyoD during murine myogenic cell differentiation. PLoS One 9: e87237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hayflick L. 1973. Tissue culture methods and applications. Academic Press, New York. [Google Scholar]
  14. Humphreys DT, Westman BJ, Martin DI, Preiss T. 2005. MicroRNAs control translation initiation by inhibiting eukaryotic initiation factor 4E/cap and poly(A) tail function. Proc Natl Acad Sci 102: 16961–16966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lee YS, Dutta A. 2007. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 21: 1025–1030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Li W, Ross-Smith N, Proud CG, Belsham GJ. 2001. Cleavage of translation initiation factor 4AI (eIF4AI) but not eIF4AII by foot-and-mouth disease virus 3C protease: identification of the eIF4AI cleavage site. FEBS Lett 507: 1–5. [DOI] [PubMed] [Google Scholar]
  17. Lin CJ, Cencic R, Mills JR, Robert F, Pelletier J. 2008. c-Myc and eIF4F are components of a feedforward loop that links transcription and translation. Cancer Res 68: 5326–5334. [DOI] [PubMed] [Google Scholar]
  18. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods 25: 402–408. [DOI] [PubMed] [Google Scholar]
  19. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM. 2013. RNA-guided human genome engineering via Cas9. Science 339: 823–826. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Malina A, Mills JR, Cencic R, Yan Y, Fraser J, Schippers LM, Paquet M, Dostie J, Pelletier J. 2013. Repurposing CRISPR/Cas9 for in situ functional assays. Genes Dev 27: 2602–2614. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Mathonnet G, Fabian MR, Svitkin YV, Parsyan A, Huck L, Murata T, Biffo S, Merrick WC, Darzynkiewicz E, Pillai RS, et al. 2007. MicroRNA inhibition of translation initiation in vitro by targeting the cap-binding complex eIF4F. Science 317: 1764–1767. [DOI] [PubMed] [Google Scholar]
  22. Mayr C, Hemann MT, Bartel DP. 2007. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 315: 1576–1579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Meijer HA, Kong YW, Lu WT, Wilczynska A, Spriggs RV, Robinson SW, Godfrey JD, Willis AE, Bushell M. 2013. Translational repression and eIF4A2 activity are critical for microRNA-mediated gene regulation. Science 340: 82–85. [DOI] [PubMed] [Google Scholar]
  24. Nielsen PJ, Trachsel H. 1988. The mouse protein synthesis initiation factor 4A gene family includes two related functional genes which are differentially expressed. EMBO J 7: 2097–2105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Nielsen PJ, McMaster GK, Trachsel H. 1985. Cloning of eukaryotic protein synthesis initiation factor genes: isolation and characterization of cDNA clones encoding factor eIF-4A. Nucleic Acids Res 13: 6867–6880. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Pelletier J, Graff J, Ruggero D, Sonenberg N. 2015. Targeting the eIF4F translation initiation complex: a critical nexus for cancer development. Cancer Res 75: 250–263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Pillai RS, Bhattacharyya SN, Artus CG, Zoller T, Cougot N, Basyuk E, Bertrand E, Filipowicz W. 2005. Inhibition of translational initiation by Let-7 microRNA in human cells. Science 309: 1573–1576. [DOI] [PubMed] [Google Scholar]
  28. Ravi A, Gurtan AM, Kumar MS, Bhutkar A, Chin C, Lu V, Lees JA, Jacks T, Sharp PA. 2012. Proliferation and tumorigenesis of a murine sarcoma cell line in the absence of DICER1. Cancer Cell 21: 848–855. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Rogers GW Jr, Komar AA, Merrick WC. 2002. eIF4A: the godfather of the DEAD box helicases. Prog Nucleic Acid Res Mol Biol 72: 307–331. [DOI] [PubMed] [Google Scholar]
  30. Wang B, Love TM, Call ME, Doench JG, Novina CD. 2006. Recapitulation of short RNA-directed translational gene silencing in vitro. Mol Cell 22: 553–560. [DOI] [PubMed] [Google Scholar]
  31. Wang B, Li S, Qi HH, Chowdhury D, Shi Y, Novina CD. 2009. Distinct passenger strand and mRNA cleavage activities of human Argonaute proteins. Nat Struct Mol Biol 16: 1259–1266. [DOI] [PubMed] [Google Scholar]
  32. Williams-Hill DM, Duncan RF, Nielsen PJ, Tahara SM. 1997. Differential expression of the murine eukaryotic translation initiation factor isogenes eIF4AI and eIF4AII is dependent upon cellular growth status. Arch Biochem Biophys 338: 111–120. [DOI] [PubMed] [Google Scholar]
  33. Yoder-Hill J, Pause A, Sonenberg N, Merrick WC. 1993. The p46 subunit of eukaryotic initiation factor (eIF)-4F exchanges with eIF-4A. J Biol Chem 268: 5566–5573. [PubMed] [Google Scholar]

Articles from RNA are provided here courtesy of The RNA Society

RESOURCES